射波刀治疗局部进展期胰腺癌临床疗效分析  

Clinical efficacy of CyberKnife radiotherapy for locally advanced pancreatic carcinoma

作　　者：宋勇春[1] 袁智勇[1] 李丰彤[1] 董洋[1] 庄洪卿[1] 王境生[1] 陈华明[1] 王平[1] 

机构地区：[1]国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室天津医科大学肿瘤医院放疗科射波刀中心,天津300060

出　　处：《中华放射肿瘤学杂志》2015年第4期392-394,共3页Chinese Journal of Radiation Oncology

摘　　要：目的：评价射波刀治疗局部进展期胰腺癌的有效性和安全性。方法回顾分析2006—2014年间接受射波刀治疗的59例局部进展期胰腺癌患者资料。肿瘤体积为13．0～125.1 cm3（中位数27.1 cm3）。处方剂量为35～50 Gy （中位数45 Gy），分割次数为3～8次（中位数5次）。采用 CT 为基础的评价有无进展。采用 Kaplan.Meier 法线计算 OS 和局部无进展生存 LPFS。结果1、2年样本数分别为26、17例，1、2年OS 分别为54％、35％，LPFS 分别为91％、70％；中位 OS 期为12.5个月，LPFS 期为10.9个月。1～2级急性和晚期胃肠道反应总发生率为61％，其中1例为3级晚期胃肠道反应者临床表现为肠道不全梗阻。结论采用射波刀治疗局部进展期胰腺癌可获得很好疗效且并发症小。Objective To assess the efficacy and safety of CyberKnife radiotherapy in the treatment of locally advanced pancreatic carcinoma. Methods The data of 59 patients with locally advanced pancreatic carcinoma who were treated with CyberKnife radiotherapy from 2006 to 2014 were retrospectively analyzed. The tumor volume ranged from 13. 0 cm3 to 125. 1 cm3 with a median value of 27. 1 cm3 . A dose of 35.50 Gy （median value= 45 Gy） in 3.8 fractions （median value = 5 fractions） was prescribed. The tumor progression was evaluated based on computed tomography. The overall survival （OS） and local progression.free survival （ LPFS） rates were calculated using the Kaplan.Meier method. Results The 1.and 2.year sample sizes were 26 and 17, respectively. The 1.and 2.year OS rates were 54% and 35%, respectively, while the 1.and 2.year LPFS rates were 91% and 70%, respectively. The median OS and LPFS times were 12. 5 and 10. 9 months, respectively. The overall incidence of grade 1.2 acute and late gastrointestinal toxicity was 61%. One patient with grade 3 late gastrointestinal toxicity had incomplete intestinal obstruction. Conclusions CyberKnife radiotherapy can achieve excellent treatment outcomes and mild complications in the treatment of locally advanced pancreatic carcinoma.

关 键 词：胰腺肿瘤/ 射波刀疗法 治疗结果 不良反应 

分 类 号：R735.9[医药卫生—肿瘤]